Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537817
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
Study to Evaluate HT-4253 in Healthy Subjects
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 First-in-Human Randomized Placebo-Controlled Double-Blind Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single Ascending Doses SAD and Multiple Ascending Doses MAD of Oral HT-4253 in Healthy Adults
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objectives of this study are to evaluate the safety and tolerability of HT-4253 when administered as single oral doses and multiple oral doses at escalating dose levels in healthy volunteer subjects
The secondary objectives of this study are to characterize the pharmacokinetics PK and pharmacodynamics PD of HT-4253
The secondary objectives of this study are to characterize the pharmacokinetics PK and pharmacodynamics PD of HT-4253
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None